Partial Prostate Salvage High Dose Rate Brachytherapy

Appropriately selected patients with histologically documented recurrence 3 years or more after initial external beam radiotherapy will undergo mpMRI for identification of the site of recurrence. A planning transrectal ultrasound (TRUS) will be obtained for fusion with the mpMRI and transposition of the target volume (GTV=gross tumor volume). A margin of 4.5 cm will be added to the GTV to create a focal planning target volume (PTV). The margin may be cropped at the interface with critical organs. Two fractions of HDR brachytherapy will be delivered, each from a single implant, 2 weeks apart. Following treatment patients will be monitored for toxicity and quality of life using the Expanded Prostate cancer Index (EPIC) questionnaire as well as the International Prostate Symptom score. Efficacy will be evaluated by monitoring the Prostate Specific Antigen (PSA) and if PSA is rising during follow-up, PSMA PET will be ordered when clinically indicated..

Inclusion criteria

• Age >45 and Life expectancy >10 years
• Previous External Beam Radiotherapy (EBRT) or LDR brachytherapy w
• > 3 year interval since EBRT or LDR Brachytherapy
• No late toxicity from prior EBRT ≥ grade 2
• PSA > nadir + 2 ng/ml and < 10 ng/ml
• PSA Doubling time > 6 months
• Radiographic evidence corresponding with site of recurrence in an under-dosed or untreated site. The recurrence should correspond to the site of original disease or be located in the seminal vesical +/- adjacent prostate as only area of recurrence (i.e. unifocal recurrence).
• Per Investigator, recurrence is suitable for implant with HDR brachytherapy and patient is suitable for procedure under anesthesia, spinal or general.
• Negative staging of the abdomen/pelvis and bones.
• Willing to provide informed consent

Exclusion criteria

• Not compliant with criteria above
• Unable to give informed consent